Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799453 | 0.99 | POLB (0.48) | POLBG6PDSERPINE1MAPTLMNA | |
| SCHEMBL1798678 | 0.89 | MAPT (0.42) | POLBG6PDSERPINE1MAPTLMNA | |
| SCHEMBL1797143 | 0.89 | MAPT (0.44) | POLBMAPTLMNAKDM4EGAA | |
| SCHEMBL1795944 | 0.88 | SERPINE1 (0.45) | POLBG6PDSERPINE1LMNAKDM4E | |
| SCHEMBL1015135 | 0.81 | GRIK1 (0.51) | POLBG6PDSERPINE1MAPTKDM4E | |
| SCHEMBL1015269 | 0.80 | GRIK1 (0.52) | POLBG6PDSERPINE1MAPTKDM4E | |
| SCHEMBL1796795 | 0.79 | LMNA (0.45) | MAPTLMNAKDM4EGAAHSD17B10 | |
| SCHEMBL1796227 | 0.78 | SERPINE1 (0.53) | POLBG6PDSERPINE1MAPTLMNA | |
| SCHEMBL1013461 | 0.78 | SERPINE1 (0.56) | POLBG6PDSERPINE1MAPTLMNA | |
| SCHEMBL1797141 | 0.78 | SERPINE1 (0.55) | POLBG6PDSERPINE1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | POLB 2674/4885G6PD 815/4885SERPINE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.